NZ760790A - Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof - Google Patents
Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereofInfo
- Publication number
- NZ760790A NZ760790A NZ760790A NZ76079015A NZ760790A NZ 760790 A NZ760790 A NZ 760790A NZ 760790 A NZ760790 A NZ 760790A NZ 76079015 A NZ76079015 A NZ 76079015A NZ 760790 A NZ760790 A NZ 760790A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pharmaceutical compositions
- vmat2 inhibitor
- antipsychotic drug
- vmat2
- antipsychotic
- Prior art date
Links
- 230000000561 anti-psychotic effect Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937223P | 2014-02-07 | 2014-02-07 | |
| NZ723107A NZ723107A (en) | 2014-02-07 | 2015-02-06 | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ760790A true NZ760790A (en) | 2022-11-25 |
Family
ID=52589782
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ760790A NZ760790A (en) | 2014-02-07 | 2015-02-06 | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| NZ723107A NZ723107A (en) | 2014-02-07 | 2015-02-06 | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ723107A NZ723107A (en) | 2014-02-07 | 2015-02-06 | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9782398B2 (enExample) |
| EP (2) | EP3102239A1 (enExample) |
| JP (4) | JP6718376B2 (enExample) |
| KR (1) | KR102328058B1 (enExample) |
| CN (3) | CN113368110A (enExample) |
| AU (1) | AU2015213778B2 (enExample) |
| CA (1) | CA2938581C (enExample) |
| IL (1) | IL247127B (enExample) |
| MX (1) | MX378664B (enExample) |
| NZ (2) | NZ760790A (enExample) |
| RU (2) | RU2021128797A (enExample) |
| WO (1) | WO2015120317A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3936130T1 (sl) * | 2014-05-06 | 2024-05-31 | Neurocrine Biosciences, Inc., | Režim odmerjanja valbenazina za zdravljenje hiperkinetičnih gibalnih motenj |
| WO2016127133A1 (en) * | 2015-02-06 | 2016-08-11 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| ES2972600T3 (es) | 2015-10-30 | 2024-06-13 | Neurocrine Biosciences Inc | Sales de diclorhidrato de valbenazina y polimorfos de las mismas |
| DK3394057T3 (da) | 2015-12-23 | 2022-04-11 | Neurocrine Biosciences Inc | Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat) |
| ES2811048T3 (es) | 2016-06-29 | 2021-03-10 | Crystal Pharmaceutical Suzhou Co Ltd | Formas cristalinas de NBI-98854, método de preparación para las mismas y uso de las mismas |
| TW202515564A (zh) * | 2016-12-02 | 2025-04-16 | 美商紐羅克里生物科學有限公司 | 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途 |
| US11337932B2 (en) | 2016-12-20 | 2022-05-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| CN110087640A (zh) | 2016-12-20 | 2019-08-02 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
| JP7199359B2 (ja) | 2017-01-27 | 2023-01-05 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
| BR112020005373A2 (pt) | 2017-09-21 | 2020-09-24 | Neurocrine Biosciences Inc. | formulação de valbenazina em alta dosagem e composições, métodos e kits relacionados com valbenazina |
| SG11202003194YA (en) | 2017-10-10 | 2020-05-28 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| US11339158B2 (en) | 2017-12-26 | 2022-05-24 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof |
| TWI832854B (zh) | 2018-04-25 | 2024-02-21 | 美商神經治療股份有限公司 | 丁苯那嗪經皮輸送裝置 |
| ES2959158T3 (es) * | 2018-05-04 | 2024-02-21 | Korea Inst Radiological & Medical Sciences | Composición de potenciación de la sensibilidad a la radiación que contiene aripiprazol como principio activo |
| TW202011963A (zh) | 2018-06-14 | 2020-04-01 | 美商紐羅克里生物科學有限公司 | Vmat2抑制劑化合物、組合物及其相關方法 |
| CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| MA53239A (fr) * | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences Inc | Procédés d'administration de certains inhibiteurs de vmat2 |
| WO2020188551A1 (en) * | 2019-03-20 | 2020-09-24 | Bol Pharma Ltd. | Methods and compositions for treating autism spectrum disorder and associated disorders |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| BR112023026691A2 (pt) * | 2021-06-30 | 2024-03-05 | Neurocrine Biosciences Inc | Valbenazina para uso no tratamento complementar de esquizofrenia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5777697A (en) * | 1980-11-04 | 1982-05-15 | Nippon Zoki Pharmaceut Co Ltd | Physiologically active substance nsq |
| JPS57209225A (en) * | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
| US5204329A (en) * | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| WO2000024399A1 (en) | 1998-10-23 | 2000-05-04 | Sepracor Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| PT1855677E (pt) | 2005-08-06 | 2009-01-13 | Cambridge Lab Ireland Ltd | 3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses |
| AU2007317242B2 (en) | 2006-11-08 | 2013-08-01 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
| GB2463452A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| US8524733B2 (en) * | 2008-09-18 | 2013-09-03 | Auspex Pharmaceuticals | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| JP2013501810A (ja) * | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル（バルバドス）エスアールエル | 医薬組成物 |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
-
2015
- 2015-02-06 CN CN202110257206.2A patent/CN113368110A/zh active Pending
- 2015-02-06 JP JP2016549493A patent/JP6718376B2/ja active Active
- 2015-02-06 EP EP15706596.2A patent/EP3102239A1/en not_active Withdrawn
- 2015-02-06 CN CN201580009498.0A patent/CN106061506A/zh active Pending
- 2015-02-06 MX MX2016010071A patent/MX378664B/es unknown
- 2015-02-06 NZ NZ760790A patent/NZ760790A/en unknown
- 2015-02-06 KR KR1020167024297A patent/KR102328058B1/ko active Active
- 2015-02-06 EP EP21216409.9A patent/EP4049681A1/en active Pending
- 2015-02-06 RU RU2021128797A patent/RU2021128797A/ru unknown
- 2015-02-06 WO PCT/US2015/014893 patent/WO2015120317A1/en not_active Ceased
- 2015-02-06 CA CA2938581A patent/CA2938581C/en active Active
- 2015-02-06 US US15/116,786 patent/US9782398B2/en active Active
- 2015-02-06 NZ NZ723107A patent/NZ723107A/en unknown
- 2015-02-06 AU AU2015213778A patent/AU2015213778B2/en active Active
- 2015-02-06 CN CN202110257547.XA patent/CN113413385A/zh active Pending
- 2015-02-06 RU RU2016135930A patent/RU2757221C2/ru active
-
2016
- 2016-08-04 IL IL247127A patent/IL247127B/en active IP Right Grant
-
2017
- 2017-09-11 US US15/701,311 patent/US20180085364A1/en not_active Abandoned
-
2019
- 2019-01-16 US US16/248,855 patent/US20190381029A1/en not_active Abandoned
- 2019-05-07 JP JP2019087459A patent/JP2019116515A/ja not_active Withdrawn
-
2020
- 2020-03-13 US US16/817,723 patent/US20200206215A1/en not_active Abandoned
-
2021
- 2021-03-02 JP JP2021032320A patent/JP2021080294A/ja active Pending
-
2023
- 2023-11-17 JP JP2023195803A patent/JP2024003253A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160132830A (ko) | 2016-11-21 |
| CN113413385A (zh) | 2021-09-21 |
| IL247127A0 (en) | 2016-09-29 |
| AU2015213778B2 (en) | 2020-04-23 |
| JP2019116515A (ja) | 2019-07-18 |
| JP2021080294A (ja) | 2021-05-27 |
| IL247127B (en) | 2021-04-29 |
| KR102328058B1 (ko) | 2021-11-17 |
| US20180085364A1 (en) | 2018-03-29 |
| CA2938581C (en) | 2023-02-28 |
| US9782398B2 (en) | 2017-10-10 |
| NZ723107A (en) | 2022-11-25 |
| MX2016010071A (es) | 2017-04-27 |
| WO2015120317A1 (en) | 2015-08-13 |
| MX378664B (es) | 2025-03-10 |
| RU2021128797A (ru) | 2021-11-26 |
| RU2757221C2 (ru) | 2021-10-12 |
| CA2938581A1 (en) | 2015-08-13 |
| AU2015213778A1 (en) | 2016-08-18 |
| JP2017505316A (ja) | 2017-02-16 |
| RU2016135930A (ru) | 2018-03-15 |
| JP6718376B2 (ja) | 2020-07-08 |
| US20200206215A1 (en) | 2020-07-02 |
| US20160339011A1 (en) | 2016-11-24 |
| CN106061506A (zh) | 2016-10-26 |
| EP4049681A1 (en) | 2022-08-31 |
| CN113368110A (zh) | 2021-09-10 |
| RU2016135930A3 (enExample) | 2018-10-05 |
| JP2024003253A (ja) | 2024-01-11 |
| EP3102239A1 (en) | 2016-12-14 |
| US20190381029A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ760790A (en) | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof | |
| ZA202308495B (en) | Pharmaceutical compositions of therapeutically active compounds | |
| DK3236943T3 (da) | Sammensætninger til ileo-jejunal lægemiddeladministration | |
| MX2021001231A (es) | Compuestos heterociclicos y sus usos. | |
| IL253123B (en) | Preparations for administration through the skin and their uses | |
| MX2020005181A (es) | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). | |
| GEP20217239B (en) | Pharmaceutical composition | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| PH12016501788B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
| MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
| ZA201605263B (en) | Pharmaceutical composition for topical administration | |
| GEP20217240B (en) | Pharmaceutical composition | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX2015008588A (es) | Composiciones y metodos para la transfeccion de polinucleótidos. | |
| EP3202417A4 (en) | Vaccine pharmaceutical composition for transdermal administration | |
| ZA201703764B (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
| GEP20217236B (en) | Composition comprising pentose and polyphenolic compound | |
| SI3236952T1 (sl) | Farmacevtski sestavek v obliki tablet | |
| ZA201500995B (en) | Low dose pharmaceutical composition | |
| HK1231750A1 (en) | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof | |
| ZA201606135B (en) | Pharmaceutical compositions of therapeutically active compounds | |
| TH1501006784A (th) | องค์ประกอบทางเภสัชกรรมขนาดยาต่ำ | |
| GB201409272D0 (en) | Synergistic combination of analgesic drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 FEB 2025 BY COMPUTER PACKAGES INC Effective date: 20240117 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 FEB 2026 BY COMPUTER PACKAGES INC Effective date: 20250117 |